Breast Cancer Screening Among Medical Staff in Tehran, Iran: Improvement of Early Detection

Hossein Yahyazadeh, Marzieh Beheshti, Azita Abdollahinejad, Maria Hashemian, Narges Sistany Allahabadi, Sahel Valadan Tahbaz

Clinical Cancer Research Center, Milad General Hospital, Tehran, Iran

Received: 12 Aug. 2019; Accepted: 28 Nov. 2019

Abstract - Breast cancer is the most prevalent Iranian female malignancy. Breast screening reduces the number of malignant breast diseases. We aimed to assess the results of the pilot breast cancer screening on early detection in female medical staff in Milad Hospital, Tehran, Iran. A cross-sectional study. Female medical staff from Milad Hospital, Tehran, Iran, were examined by a specialist in 2016. A checklist, including demographic data, was completed by the participants. If necessary, they referred to as sonography or mammography. Data were analyzed using SPSS software. Of 746 people enrolled, 137 had no pathological point, 609 had suspicious or positive findings that were referred for further investigation, 449 had normal findings, and 7 had suspicious mass and were biopsied, 6 were benign. One case had primary invasive cancer. Since screening for breast cancer helps to early detection of this disease, the implementation of cancer screening programs should be on the priority of health authorities.

Key words: Breast carcinoma; Breast neoplasm; Breast cancer detection; Screening mammography; Iran

Introduction

The leading cause of women cancer-related deaths worldwide is breast cancer (1). The approximate incidence rate of breast cancer is 1.15 million women, and based on WHO reports, it increased 1%-2% in a year, and 50%, 502.000 of that occurs in developing countries (2,3).

Early diagnosis (tumor <2cm) is a positive prognostic factor and increases the long-term survival of the patients. In higher-risk patients, the early detection of breast cancer (mammography) is a routine part of regular medical examination. The information, knowledge, and awareness of breast cancer are important individual factors of breast cancer early detection, so many women miss it due to a lack of those factors. The lack of breast cancer screening and without screening facilities can cause breast cancer diagnosis in advance stage (1). Mammography screening reduces breast cancer mortality among women 40 to 74 yr of age (4).

In Iran, the total incidence rate and the stage of diagnosis are increasing, and the onset age is about 10 yr younger than western countries (2).

The incidence rate increase in the age group of 40-44-yr-old is 6.2%, in 45-49-yr-old 3.5%, and in 55-59-yr-old is 5.3% (5).

There are different suggested methods for early detection of breast cancer like breast self-examination (BSE), clinical breast examination, and mammography (6). The factor that affects performing BSE is about its importance and proper performing way (7).

To assess the efficacy of early diagnosis protocol for female medical staff, we conducted a screening program for them in Milad Hospital, Tehran, Iran.

Materials and Methods

This cross-sectional study was conducted in Milad Hospital in 2016 to assess the early breast cancer screening program on female staff. All of 1300 women staff (over 20 yr) invited, but only 746 women participated.

We asked all the participants to perform a self-breast examination at the beginning of the study and then completed by them a checklist containing demographic and clinical data like age, marital status, age of
Breast cancer screening

menarche, pregnancy history, OCP use, age and type of menopause, family history of various types of cancers, including breast cancer. In the following, the result of the self-breast examination completed by the staff in the checklist. Then, all the entries examined by a female breast surgeon. All stages of patient examination and follow up were based on NCCN Guideline 2016 (8).

In the following, we performed mammography and sonography. For suspected women under 40-yr-old age, sonography was performed.

Assessed demographic data were selected based on the general of the national breast cancer control program of the Islamic Republic Iran prevention, such as early menarche, first live birth age after 30 yr, menopause age after 55 yr, hormone therapy, pregnancy medications, breastfeeding less than two-year, BMI 30 and more than 30, family history of breast malignancy, history of breast surgery, personal history of other cancers (9).

We received informed consent from all participants. This study was approved by the Ethics Committee of Milad Hospital.

We performed a descriptive analysis of all of the variables on the dataset, including age, marital status, history of medical education, age at menarche, etc. by tests like mean, frequency, std. Deviation, by SPSS ver. 16 (Chicago, IL, USA).

Results

Of 1300 staff women in Milad Hospital, 746 women between 21 and 58 yr, participated in this study and were examined by a breast surgeon.

The mean age of the participant was 35.7±5.7, and the mean age at menarche was 13.4±1.5-yr-old. In assessed demographic data, most of the participants were married (358, 76.1%) and 525 (70.3%) women educated in fields of medical sciences. Of the total, history of pregnancy, breastfeeding, taking OCP (Oral contraceptive), taking pregnancy medications and first live birth age over than 30 yr was 441 (59.1%), 392 (52.5%), 215 (28.8%), 39 (5.2%) and 277 (37.1%) respectively. The mean of duration taking OCP and pregnancy medications was 15.3 and 12 months, respectively. Nineteen (2.5%) were menopause, and menopause age of 18 (2.4%) was over 55 yr. BMI for 620 (83.1%) was <30. Only 62 (8.3%) had at least one family history of breast cancer (Tables 1, 2).

| Demographic nominal data                  | subjects (n=746) | Percent (%) |
|------------------------------------------|-----------------|-------------|
| Marital status                           |                 |             |
| Married                                  | 358             | 76.1        |
| Single                                   | 166             | 22.3        |
| Unknown                                  | 12              | 1.6         |
| Medical education                        |                 |             |
| Yes                                      | 525             | 70.3        |
| No                                       | 221             | 29.7        |
| Pregnancy                                |                 |             |
| No                                       | 286             | 38.3        |
| Unknown                                  | 19              | 2.5         |
| Yes                                      | 392             | 52.5        |
| Breastfeeding                            |                 |             |
| No                                       | 322             | 43.2        |
| Unknown                                  | 32              | 4.3         |
| Yes                                      | 215             | 28.8        |
| Oral contraceptive                       |                 |             |
| No                                       | 455             | 61.0        |
| Unknown                                  | 76              | 10.2        |
| Yes                                      | 39              | 5.2         |
| Pregnancy medications                    |                 |             |
| No                                       | 628             | 84.2        |
| Unknown                                  | 79              | 10.6        |
| Yes                                      | 19              | 2.5         |
| Menopause                                |                 |             |
| No                                       | 727             | 97.4        |
| Natural                                  | 12              | 63.2        |
| Natural                                  | 1               | 5.3         |
| Menopause type                           |                 |             |
| Medicine                                 | 6               | 31.6        |
| Surgery                                  |                 |             |
| Family history of breast malignancy      |                 |             |
| Yes                                      | 62              | 8.3         |
| No                                       | 684             | 91.7        |
| Hormone therapy                          |                 |             |
| Yes                                      | 72              | 9.7         |
| No                                       | 577             | 77.3        |
| Unknown                                  | 97              | 13.0        |
| Anti-estrogen therapy                    |                 |             |
| No                                       | 600             | 80.4        |
| Unknown                                  | 128             | 17.2        |
Table 2. Demographic numerical data

| Demographic numerical data       | subjects (n=746) | Percent (%) |
|---------------------------------|-----------------|-------------|
| Age (yr)                        |                 |             |
| <40                             | 562             | 75.3        |
| ≥40                             | 184             | 24.6        |
| Age at menarche (yr)            |                 |             |
| <11                             | 74              | 9.9         |
| ≥11                             | 641             | 85.9        |
| Unknown                         | 31              | 4.2         |
| First live birth age            |                 |             |
| < 30 yr                         | 277             | 37.1        |
| ≥ 30 yr                         | 134             | 17.9        |
| Breastfeeding duration (months) |                 |             |
| <24                             | 217             | 29.0        |
| ≥24                             | 162             | 21.7        |
| Unknown                         | 13              | 1.7         |
| Menopause age (yr)              |                 |             |
| <55                             | 18              | 2.4         |
| ≥55                             | 1               | 0.1         |
| Body mass index (kg/m²)         |                 |             |
| <30                             | 620             | 83.1        |
| ≥30                             | 55              | 7.3         |
| Unknown                         | 71              | 9.5         |

One hundred six participants (22.2%) had at least one chronic disease of the pulmonary, cardiovascular or thyroid, 6 had different history types of cancers (uterine 1, 0.1% - ovarian cancer 2, 0.3% - colon cancer 3, 0.4%) and 16 (1.7%) had a history of breast surgery.

Based on the NCCN protocol, in step one, all patients physically examined by the surgeon and 137 (18.3%) had no clinical findings. Overall, 609 suspect women (81.6%) referred to sonography (N=463, 62.06%) or mammography (N=146, 19.57%).

In total, 456 performed imaging ordered, and others refused to continue the project, 449 (60.18% of total and 98.4% of who performed imaging) were normal or with a fibrocystic or benign change in the breast (BI-RADS 1 and 2). Seven (0.53% of total and 1.53% of who performed imaging) had suspect mass (BI-RADS 4), and biopsy for them performed. Six diagnosed normal mass, and 1 diagnosed with primary Invasive breast cancer stage IIA and referred to related treatment (Figure 1).
Discussion

In recent years, due to techniques of early detection and treatment improvement, the mortality rate of breast cancer has decreased. However, in European women, breast cancer is still the leading cause of death due to cancer (10). The aim of this study was to perform breast cancer screening for medical staff and determine the rate of breast cancer in these staff.

Although breast cancer at a young age is rare, it is a bad prognostic factor (11). In Karachi, Pakistan, between the years 1995 and 1997, the incidence of breast cancer in ages 15-24 and 25-37 were 2.9% and 27.4%, respectively, which was the highest cancer presentation at these age groups (11). The importance of design breast cancer screening programs in women with any symptom and screening should not be limited to older age (11).

American Cancer Society recommends that women in the 20s and 30s, every 3 years should be clinical breast examined by a health professional (11). In our study, most participants have less than 40 yr, and the mean age was 35.7 (+5.7). Most of the exposure to risk factors was in age groups 30-44 yr (9). Moreover, the mean age of patients with breast cancer was 41.5 (+5.6) (12).

According to the national cancer institute’s PDQ (Physician Data Query) cancer information summary about breast cancer, early menarche, defines as the beginning of menstrual periods at or before age 11, consider as a risk factor for breast cancer and each year delay in the age of menarche, reduces the risk of breast cancer by 6% (11). In our study, 9.9% reported having had early menarche in comparison that early menarche was in 3.3% (11). This factor puts them exposed to the risk of breast cancer.

For every 12 months of breastfeeding, breast cancer decreased by 4.3% (9). In our study, 162 (21.7%) had ≥ 24 months duration of breastfeeding. In Turkey, women with a positive history of breast cancer in a first-degree relative had higher breast cancer risk 5.7 times more than those with negative family history. About 6% and 15% of positive family history were reported for breast cancer, respectively. In our study, 62 (8.3%) have a positive family history of breast cancer (11,13).

In premenopausal women, the lower BMI has a higher risk of breast cancer due to irregular menstrual cycles and cycles without ovulation (9,11). In our study, 97.4% were not menopause, and 83.1% had <30 BMI, and they were at increased risk of breast cancer. 10.3% of participants were underweight (11).

In Norway and Sweden, ever used OCP’s in life, increases breast cancer risk more than 30% (14). Overall, 5% had a positive history of OCP’s use, while in our study, it is 215 (28.8%) (11).

The overall cancer detection rate was 0.004% 15 and in our study, this rate was 0.1%; also, findings BI-RADS 1 and 2, BI-RADS 3 and BI-RADS 4 was 85.6%, 12.5%, and 1.9% respectively. BI-RADS 1 and 2 were less than our study, and BI-RADS 4 was slightly more than our study.

With training improvement of lifestyle and reduced risk factors, can be decreased incidence of breast cancer. According to effects items on breast cancer, i.e., low physical activity, cigarette smoking, repeated exposure to radiations, etc. suggested that assessed this item and data about participants will more complete in future studies.

Limitation of this study was not interested of staffs to participate of this study; to solve this problem should increase the awareness of women about risk factors of breast cancer and effects of screening to early detection of malignancy.

Early diagnosis can diagnose breast cancer in the early stages. Screening leads to early detection and reduced mortality. Regular screening programs in the community and the provision of screening facilities throughout the country can improve early diagnosis.

Acknowledgments

This research was supported by Elite Researcher Grant Committee under award number [24906] by Milad General Hospital- Iranian Social Security organization, Tehran, Iran.

References

1. Demirkiran F, Balkaya NA, Memis S, Turk G, Ozvurmaz S, Tuncyurek P. How do nurses and teachers perform breast self-examination: are they reliable sources of information? BMC Public Health 2007;7:96.
2. Montazeri A, Vahdaninia M, Harirchi I, Harirchi AM, Sajadian A, Khaledi F, et al. Breast cancer in Iran: need for greater women awareness of warning signs and effective screening methods. Asia Pac Fam Med 2008;7:6.
3. Thomas E, Escandon S, Lamyian M, Ahmadi F, Setoode SM. Exploring Iranian women's perceptions regarding control and prevention of breast cancer. Qual Rep
4. Humphrey LL, Helfand M, Chan B KS, Woolf SH. Breast cancer screening: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;137:347-60.

5. Rafieianesh H, Salehiniya H, Lotfi Z. Breast Cancer in Iranian Woman: Incidence by Age Group, Morphology and Trends. Asian Pac J Cancer Prev 2016;17: 1393-7.

6. Babu GR, Samari G, Cohen SP, Mahapatra T, Wahbe RM, Mermash S. et al. Breast cancer screening among females in Iran and recommendations for improved practice: a review. Asian Pac J Cancer Prev 2011;12:1647-55.

7. Montazeri A. Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008:27:32.

8. Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, et al. NCCN clinical practice guideline in oncology. Breast cancer screening and diagnosis. J Natl Compr Canc Netw 2009;7:1060-96

9. Roohiparvarzade N, Ghaderi M, Parsa A, Allahyari A. Prevalence of risk factors for breast cancer in women (20 to 69 Years old) in Isfahan 2012-2013. Iranian Journal of Breast Diseases 2014;7:52-61.

10. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26:8-30.

11. Memon ZA, Kanwal N, Sami M, Azam Larik P, Zain Farooq M. Risk of Breast Cancer among Young Women and Importance of Early Screening. Asian Pac J Cancer Prev 2015;16:7485-9.

12. Fathi Najafi T, Jabarzadeh Ganjeh S, Mojahedi Rezaian S, Mazloom SR. Assessment of Certain Breast Cancer Risk Factors During Reproductive Age in Women in Mashhad(2002-2003). Razi Journal of Medical Science 2004;11:577-85.

13. Pandey S, Chandravati. Breast Screening in North India: A Cost-Effective Cancer Prevention Strategy. Asian Pac J Cancer Prev 2013;14:853-7.

14. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women’s Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002;11:1375-81.

15. Kayhan A, Gurdal SO, Ozaydin N, Cabioglu N, Ozturk E, Ozcinar B, et al. Successful First Round Results of a Turkish Breast Cancer Screening Program with Mammography in Bahcesehir, Istanbul. Asian Pac J Cancer Prev 2014;15:1693-7.